<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03609294</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FLC-CT-102</org_study_id>
    <nct_id>NCT03609294</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, 3x3 Partial Replicated Crossover Study to Evaluate the Pharmacokinetics and Safety/Tolerability Between a Fixed Dose Combination of Fimasartan 120 mg/Linagliptin 5 mg and Co-administration of Fimasartan 120 mg and Linagliptin 5 mg in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics and safety/tolerability when
      administrated fixed dose combination of Fimasartan/Linagliptin and when co-administrated
      Fimasartan and Linagliptin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, 3x3 partial replicated crossover study to evaluate the
      pharmacokinetics and safety/tolerability. Within each period, randomized subjects will be 2
      dosing regimens with a fixed dose combination of Fimasartan/Linagliptin and co-administration
      of Fimasartan and Linagliptin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2018</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">March 4, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Fimasartan: 0-48 hours after administration, Linagliptin: 0-72 hours after administration</time_frame>
    <description>Maximum concentration of drug in plasma of Fimasartan, Linagliptin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>Fimasartan: 0-48 hours after administration, Linagliptin: 0-72 hours after administration</time_frame>
    <description>Area under the plasma drug concentration-time curve over the time interval from 0 to the last observed plasma concentration of Fimasartan, Linagliptin</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Hypertension</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1(Treatment A) - Period 2(Treatment A) - Period 3(Treatment B)
There will be a washout of 35 days between the each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1(Treatment A) - Period 2(Treatment B) - Period 3(Treatment A)
There will be a washout of 35 days between the each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequency C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1(Treatment B) - Period 2(Treatment A) - Period 3(Treatment A)
There will be a washout of 35 days between the each period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A (Fimasartan, Linagliptin)</intervention_name>
    <description>Co-administration of Fimasartan and Linagliptin</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequency C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B (Fimasartan/Linagliptin)</intervention_name>
    <description>Fixed Dose Combination of Fimasartan 120 mg/Linagliptin 5 mg</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequency C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male 19-50 years of age.

          2. Body mass index (BMI) ≥ 18 and ≤ 27 kg/m2 at screening.

          3. Understands the study procedures in the Informed consent form (ICF), and be willing
             and able to comply with the protocol.

          4. Medically healthy with no clinically significant medical history.

        Exclusion Criteria:

          1. History or presence of clinically significant medical or psychiatric condition or
             disease.

          2. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg) or hepatitis C virus (HCV).

          3. Seated blood pressure is less than 100/55 mmHg or greater than 140/100 mmHg at
             screening.

          4. Plasma donation within a month prior to the first dose of study drug.

          5. Participation in another clinical trial within 3 months prior to the first dose of
             study drug(s).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Dahak-ro</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fimasartan</keyword>
  <keyword>Linagliptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

